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Stroke and Apolipoprotein E e4 Are Independent Risk
Factors for Cognitive Decline
A Population-Based Study
M.G. Dik, MSc; D.J.H. Deeg, PhD; L.M. Bouter, PhD; E.H. Corder, PhD;
A. Kok, MSc; C. Jonker, MD, PhD
Background and Purpose—Stroke and apolipoprotein Ee4 (ApoEe4) are individually important risk factors for cognitive
decline, including Alzheimer disease. It has been suggested that ApoEe4 multiplies the risk for cognitive decline
following stroke. In a population-based sample, using well-defined sensitive cognitive measures, this study investigates
whether cognitive decline following stroke is worse for patients who carry the ApoEe4 allele.
Methods—Subjects were participants in the Longitudinal Aging Study Amsterdam (LASA). The sample consisted of 1224
subjects, aged 62 to 85 years, who participated in the 3-year follow-up examination and for whom ApoE and stroke data
were complete. We assessed cognitive decline using the Mini-Mental State Examination, the Auditory Verbal Learning
Test (memory: immediate and delayed recall), and the Coding Task (information processing speed). The effects of stroke
and ApoEe4 on cognitive decline were evaluated with ANOVA and multiple logistic regression analysis, adjusted for
age, sex, education, and baseline cognition.
Results—A synergistic effect modification for stroke and ApoEe4 on cognitive decline was not observed. Unexpectedly,
instead, stroke patients carrying thee4 allele demonstrated a nonsignificantly lowered risk for Mini-Mental State
Examination decline (OR50.3; 95% CI 0.1 to 1.1). ApoEe4 was associated with declines in information processing
speed (OR51.5; 95% CI 1.1 to 2.1) and small declines for immediate and delayed recall.
Conclusions—Stroke and ApoEe4 may impair cognition through distinct nonsynergistic mechanisms. The slowing of
information processing speed for ApoEe4 carriers was more evident than impairment in memory.(Stroke.
2000;31:2431-2436.)
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Stroke often results in cognitive impairment and decline.1,2The relative risk for dementia within 4 years of ischemic
stroke is 5.5, even after exclusion of patients who were
demented within 3 months.3 Stroke affects many cognitive
processes. General slowing in information processing and
attentional deficits are prominent.4 The decline is sometimes
progressive, leading to dementia with postmortem Alzheimer
pathology.5
The established major genetic risk factor for cognitive
decline in the elderly and for late-onset Alzheimer disease is
thee4 allele for the apolipoprotein E (ApoE) gene located on
chromosome 19.6,7 The effects of ApoEe4 seem to be most
prominent on specific measures of memory function.8,9 De-
cline in memory, especially delayed recall, is an early
indicator of Alzheimer disease, especially in patients with
ApoE e4.10,11
Taken together, both stroke and ApoEe4 are associated
with cognitive decline. Furthermore, stroke and ApoEe4 may
be related to cognitive decline in a complex relationship,
possibly similar to the relationship that has been proposed
between subclinical cardiovascular factors, ApoEe4, and
cognitive decline.12 Slooter et al13 posit that the risk of ApoE
e4 on cognitive decline is independent and not mediated via
atherosclerosis. However, ApoEe4 seems to modulate the
effects of atherosclerosis on cognitive decline. Haan et al12
showed that ApoEe4 increased the risk of cognitive decline
associated with subclinical cardiovascular disease. They did
not further explore the modifying role of ApoEe4 on the
association between stroke and cognitive decline. Since many
subclinical cardiovascular factors are risk factors for stroke,14
such modification is plausible. Synergy between stroke and
ApoE e4 in regard to cognitive decline, measured by the
Mini-Mental State Examination (MMSE), has been reported
by Kalmijn et al15 among 353 community-living elderly men
but has not been confirmed. Recently, Zhu et al16 did not find
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a multiplicative effect for stroke and ApoEe4 on the risk of
dementia in 1301 subjects in the Kungsholmen cohort.
The purpose of this study is to examine the effect modifi-
cation by ApoEe4 of the association between stroke and
cognitive decline in a large population-based study, with the
use of specific measures sensitive to cognitive decline.
Subjects and Methods
Study Sample
Subjects were participants in the Longitudinal Aging Study Amster-
dam (LASA), a population-based study among 3107 subjects aged
55 to 85 years.17 The sampling and data collection procedures have
been described elsewhere in detail.18,19 In summary, a random
sample stratified by age and sex was drawn from the population
registries in 3 geographic areas of the Netherlands. Sample selection
was stratified by age and sex according to expected 5-year mortality
to ensure sufficient sample sizes for longitudinal analyses within age
and sex strata. Subjects were interviewed at home by trained
interviewers. Approval for the study was given by the local medical
ethics committee, and all respondents gave informed consent at the
start of the study.
For the present study, the study design involved additional
medical testing for subjects aged 62 years and older (n52064).
Follow-up measurements were completed for 1406 subjects (68.1%)
after an average of 3.1 (SD 0.2) years. Of the 658 subjects who were
lost to follow-up, 320 (15.5% of 2064 subjects) had died, 8 (0.4%)
could not be contacted, 107 (5.2%) were too ill to be interviewed,
and 223 (10.8%) refused.
For 167 of the 1406 subjects, ApoE could not be phenotyped
because no blood was available from these subjects (ie, they did not
agree to give blood). In addition, for 15 subjects information on
whether a stroke had occurred was missing. Therefore, our present
study sample consisted of 1224 respondents who participated in the
follow-up measurement after 3 years and for whom the ApoE and
stroke data were complete.
Cognitive Performance
Overall cognitive function was measured with the MMSE.20 Mem-
ory was measured with an abbreviated version of Rey’s Auditory
Verbal Learning Test (AVLT).21 We used 3 learning trials instead of
5 trials in Rey’s AVLT to reduce the test burden for the respondent.
In each trial, the interviewer read aloud a list of 15 words, after
which the respondents recalled as many words as they could. We
noted the number of correctly recalled words (points). Words
mentioned by the respondent that were not on the AVLT word list
were not counted. Furthermore, words that were mentioned more
than once by the respondent were counted only once (each trial).
After an interval of approximately 20 minutes, during which a
different nonverbal task was performed, the respondents were asked
to recall as many words as possible (delayed recall). Immediate
recall (score on the third trial; range, 0 to 15) and delayed recall
(range, 0 to 15) were derived from this test. At follow-up, a parallel
version of the AVLT was used. The parallel versions, which are used
in treatment research,22 were validated and tested on parallelism.23
Information processing speed was measured with the Coding
Task.24 The task consisted of 3 identical trials, each lasting 1 minute,
in which the respondent had to combine 2 characters according to a
given example. The respondent was asked to work as quickly and
accurately as possible. The score on each trial consisted of the
number of completed characters. The mean score of the 3 trials
(range, 4.7 to 43.0) was used in the analyses.
Apolipoprotein E
Serum samples were obtained and frozen at280°C until determina-
tion of ApoE phenotype. The ApoE phenotype was determined by
isoelectric focusing of delipidated serum samples, followed by
immunoblotting.25 The distribution of the ApoE phenotypes was in
Hardy-Weinberg equilibrium (ApoEe2/2, 0.7%;e2/3, 11.1%;e3/3,
61.5%; e2/4, 2.7%; e3/4, 21.3%;e4/4, 2.7%). ApoE status was
classified ase4 carriers for subjects with the ApoEe4 isoform
(phenotypese2/4, e3/4, e4/4) and as non-e4 carriers for subjects
without the ApoEe4 isoform (phenotypese2/2, e2/3, e3/3).
Stroke
History of stroke was obtained by diagnosis of the respondent’s
general practitioner (GP). Subjects who reported a stroke although
their GP did not report a stroke (n526) were considered free of
stroke. The GP was thought to have better knowledge of the stroke
diagnosis, whereas inaccurate self-reports are possibly due to label-
ing of symptoms such as dizziness or fainting as a cerebrovascular
problem.26 When information from the GP was not available
(n5211), stroke history was based on self-report. The agreement
between the patient’s self-report and the GP’s information was
moderate (k50.56). The patient’s self-report was not dependent on
cognitive impairment.26
Our study included 53 subjects who had had a stroke before the
start of our study and who participated at 3-year follow-up. Because
the cognitive decline after stroke is thought to be a continuous
process, we believed that it was important to also include the 22
stroke patients who had had a stroke during the follow-up period.
This resulted in a total of 75 stroke patients available for
longitudinal analyses.
Putative Confounders
Data on age and sex were derived from the population registries at
baseline. Education was assessed by asking the respondent for the
highest educational level completed, which was converted into total
number of years of education (range, 5 to 18 years).
Because depression is associated with both stroke27 and cognitive
decline,18,28 depression was considered a putative confounder. De-
pression was assessed with the Center for Epidemiologic Studies
Depression Scale. This is a 20-item self-report scale (range, 0 to 60)
designed to measure depressive symptomatology in the general
population. We used the generally applied cutoff score$16 to
identify clinically relevant depressive subjects.29,30
Stroke severity and time interval between stroke diagnosis and
cognitive testing may be related to ApoEe4.31 In addition, it is likely
that these stroke features influence the cognitive decline.1,4 There-
fore, we investigated whether these stroke features differed fore4
versus non-e4 carriers. Stroke severity was assessed by asking the
GP whether the patient was limited in daily living because of the
consequences of the stroke. If data from the GP were not available
(n516), self-report data were used. Response categories were on a
3-point scale, ranging from “not at all” (1) to “severe” (3). Further-
more, additional information on date of diagnosis was collected. The
time interval between stroke diagnosis and baseline cognitive testing
was calculated and categorized into,1 year, 1 to 3 years, and.3
years.
Data Analysis
Differences in baseline characteristics were evaluated between stroke
patients and subjects without stroke. Differences in ApoE status,
stroke features, and sex were evaluated with thex2 t st. Differences
in the continuous variables age and education and each cognition
score were tested with thet test for independent samples.
Cognitive change was calculated for each subject as the difference
between baseline score and follow-up score. The effects of stroke
and ApoE e4 on cognitive change were evaluated with multiple
classification analysis by ANOVA, adjusted for age, sex, education,
and baseline cognition (ie, the score of the specific cognitive test for
which the change score was evaluated). The effect modification was
evaluated by the product term Stroke3ApoEe4 at the 0.05 level of
significance. If the product term was not significant, we omitted the
term from the model.
In addition, reliable cognitive change was calculated according to
the Edwards-Nunnally method, which takes into account the reliabil-
ity of the cognitive test and regression to the mean.32 The change
scores were dichotomized into “decline” and “no decline,” with
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P,0.10 as statistical cutoff score. The analyses were performed with
multiple logistic regression models. We evaluated the effect modi-
fication by including the product term Stroke3ApoE e4 in the
model. As with ANOVA, the product term was omitted from the
model if the term was not significant (P.0.05). The logistic
regression models were adjusted for age, sex, education, and baseline
cognition score.
Results
The 53 subjects with a stroke diagnosis at the time when first
examined as part of the LASA cohort were significantly older
and performed lower on each cognition test than the 1171
subjects without a diagnosis (Table 1). The proportion of
ApoE e4 carriers among the stroke patients was higher than
among the nonpatients, but the difference was not significant.
Stroke patients with ApoEe4 had slightly lower baseline
scores on MMSE and immediate and delayed recall tests than
stroke patients without ApoEe4 (data not shown).
Table 2 shows that stroke patients with (n517) and without
(n536) thee4 allele for ApoE did not differ significantly on
stroke severity and time interval between stroke diagnosis
and cognitive testing. Since depression was not associated
with stroke (Table 1) and stroke severity and time interval
since stroke diagnosis were not associated with ApoE status,
these were not included in the multivariate analyses as
putative confounders.
For the analyses of cognitive decline, the 22 incident stroke
cases (10e41; 12e42) were added to the 53 subjects with a
stroke diagnosis at baseline. This inclusion of incident stroke
cases did not influence the results because the results of only
prevalent strokes were comparable to the results with in-
cluded incident strokes. Furthermore, the rates of cognitive
decline for prevalent and incident stroke patients were com-
parable (data not shown).
Change in cognition over time is described in Table 3 for
the 4 groups based on stroke and ApoE status. The positive
scores for the memory tests indicate improvement, consistent
with a training effect on repeated testing.33 Except for the
MMSE (P50.01), the interaction between stroke and ApoE
e4 was not significant (P50.26 for immediate recall,P50.06
for delayed recall,P50.82 for information processing speed).
Contrary to expectations, stroke patients without ApoEe4
had the lowest changes in MMSE over time compared with
the other groups. Consistent with expectations, stroke patients
with e4 showed greater declines in information processing speed
than the other groups (22.1 points versus20.8 unadjusted;
22.0 versus20.8 adjusted). However, this large difference did
not reach statistical significance, possibly because of the small
number of persons with both stroke ande4.
When we considered the subjects unaffected by a stroke,
the 300 carrying ApoEe4 tended, as expected, to have more
decline (or less improvement), as assessed by each cognitive
measure, than the 849 who did not carry ane4 allele.
However, only the decline in information processing speed
(21.4 points versus20.8) was statistically significant
(P50.01).
The odds ratios for cognitive decline over 3 years obtained
from logistic regression models are shown in Table 4.
Comparable to the results for continuous cognitive change
(ANOVA), there was no interaction between stroke and
ApoE e4, except for the MMSE. Again contrary to expecta-
tion, stratified analyses for stroke revealed a nonsignificantly
lowered risk for MMSE decline fore4 carriers in the stroke
group (OR50.3; 95% CI 0.1 to 1.1). In the nonstroke group,
the risk of MMSE decline fore4 carriers was 1.3 (1.0 to 1.9).
For decline in recall and processing speed, instead, thee4
allele for ApoE increased the risk of decline from 20% to
50% (30% to 50% when estimated with adjustment for age
and other potential confounders). This was significant for







ApoE e4, % (n) 32.1 (17) 26.5 (310)
Men, % (n) 69.8 (37) 48.3 (566)\
Depression, % (n) 15.1 (8) 11.9 (139)
Age, mean (SD), y 74.6 (6.7) 72.2 (6.6)\
Education, mean (SD), y 8.5 (3.4) 9.0 (3.4)
MMSE, mean (SD)† 26.5 (2.3) 27.4 (2.3)\
Immediate recall, mean (SD)‡ 6.8 (2.5) 7.6 (2.6)\
Delayed recall, mean (SD)‡ 4.1 (2.6) 5.0 (2.7)\
Information processing speed, mean (SD)§ 20.2 (7.9) 24.0 (7.1)\
Decline in MMSE, % (n) 28.3 (15) 18.9 (220)
Decline in immediate recall, % (n) 11.8 (6) 13.6 (155)
Decline in delayed recall, % (n) 19.6 (10) 9.7 (111)\
Decline in information processing speed,
% (n)
18.8 (9) 19.3 (215)
Some data on cognitive measures were missing.





\Significant differences (P#0.05), evaluated with the x2 test or t test.
TABLE 2. Stroke Severity and Time Interval Between










Limitations in daily living, % (n)†
None 43.8 (7) 58.3 (21)
Slight 43.8 (7) 36.1 (13)
Severe 12.4 (2) 5.6 (2)
Stroke diagnosis, % (n)
,1 y 23.5 (4) 27.8 (10)
1–3 y 35.3 (6) 25.0 (9)
.3 y 41.2 (7) 47.2 (17)
Differences (P#0.05) were evaluated with the x2 test.
*Fifty-three subjects had a history of stroke at the time of baseline
examination.
†Data of 1 subject were missing.
Dik et al Stroke and ApoE e4 Independent Risk Factors for Cognitive Decline 2433
 at Vrije on July 29, 2011http://stroke.ahajournals.org/Downloaded from 
information processing speed: the odds of decline were
1.5-fold higher fore4 carriers (95% CI 1.1 to 2.1).
The complex pattern of risk for cognitive decline led us to
further examine mortality fore41 and e42 stroke patients.
We examined mortality rates from baseline to 3-year
follow-up and found that stroke patients with and withoute4
had about the same risk of death.
Discussion
Our population-based longitudinal study supports indepen-
dent effects for stroke and ApoEe4 on cognitive decline. This
result differs from that reported by Kalmijn et al15 in that they
found a multiplicative effect of stroke and ApoEe4 on
cognitive decline, measured by the MMSE. Their finding
may be due to chance given the small size of that study (6
stroke patients carrying the ApoEe4 allele, compared with 27
stroke patients with ApoEe4 in our study). To account for
differences in study design, we defined cognitive decline as a
drop in the MMSE of.1 SD (.2 points) according to the
definition in their study, but we found no multiplicative effect
of stroke and ApoEe4 either (data not shown). Support for
independent additive effects rather than a multiplicative
effect of stroke and ApoEe4 was found in the population-
based study on incident dementia by Zhu et al.16
It seems unlikely that the results found in our study derive
from worse mortality in the stroke patients with ApoEe4
because mortality was not higher among stroke patients with
ApoE e4 than in stroke patients without ApoEe4. A higher











ApoE e4† Stroke ApoE e4
Unadjusted
MMSE‡§ 20.4 21.6 20.7 20.5 0.01 0.02 0.25
Immediate recall 0.4 20.2 0.2 0.3 NS 0.46 0.71
Delayed recall§ 0.7 20.3 0.5 0.7 NS 0.04 0.59
Information processing speed\ 22.1 21.3 21.4 20.8 NS 0.17 0.01
Adjusted¶
MMSE‡ 20.3 21.6 20.8 20.5 0.01 0.29 0.07
Immediate recall 0.0 0.1 0.2 0.2 NS 0.54 0.55
Delayed recall 0.1 0.2 0.5 0.6 NS 0.09 0.29
Information processing speed\ 22.0 21.4 21.4 20.8 NS 0.18 0.01
*The 22 patients with incident stroke were classified as Stroke1 in addition to the 53 stroke patients at baseline.
†If not significant, the interaction term was omitted from the model.
‡Significant effect modification stroke and ApoE e4 (Stroke3ApoE e4) (P#0.05).
§Significant effect stroke (P#0.05).
\Significant effect ApoE e4 (P#0.05).
¶Adjusted for age, sex, education, and baseline cognition score.
TABLE 4. ORs (95% CI) of Cognitive Decline for Stroke and ApoE e4*
Stroke3ApoE
e4† Stroke ApoE e4
Unadjusted
MMSE‡§ 0.3 (0.1–0.9) 2.5 (1.4–4.7) 1.3 (0.9–1.7)
Immediate recall NS 0.9 (0.4–1.8) 1.2 (0.9–1.8)
Delayed recall NS 1.8 (0.9–3.5) 1.3 (0.8–1.9)
Information processing speed\ NS 1.5 (0.8–2.6) 1.5 (1.1–2.0)
Adjusted¶
MMSE‡§\ 0.2 (0.1–0.9) 1.9 (1.0–3.7) 1.3 (1.0–1.9)
Immediate recall NS 0.7 (0.4–1.6) 1.3 (0.9–1.9)
Delayed recall NS 1.4 (0.7–2.9) 1.4 (0.9–2.1)
Information processing speed\ NS 1.2 (0.7–2.1) 1.5 (1.1–2.1)
*The 22 patients with incident stroke were classified as Stroke1 in addition to the 53 stroke
patients at baseline.
†If not significant, the interaction term was omitted from the model.
‡Significant effect modification stroke and ApoE e4 (Stroke3ApoE e4) (P#0.05).
§Significant effect stroke (P#0.05).
\Significant effect ApoE e4 (P#0.05).
¶Adjusted for age, sex, education, and baseline cognition score.
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mortality among ApoEe4 stroke patients has been previously
suggested in elderly subjects aged$75 years but has not been
confirmed in younger samples.31,34 Another possible source
of bias might have been introduced by differences in stroke
features between ApoEe4 and non-e4 carriers. The severity
of the stroke and the time interval between stroke diagnosis
and baseline cognitive testing did not differ by ApoEe4 in
our study and therefore could not explain the lack of an
synergistic effect modification between stroke and ApoEe4
on cognitive decline.
Still, the finding that stroke patients without ApoEe4
showed faster decline on the MMSE than the other groups
requires consideration. Most likely this is an artifact, possibly
because of the skewed distribution of the MMSE and the
small number of subjects in this particular group. In contrast,
the rate of cognitive decline on information processing speed
is highest for stroke patients carrying thee4 allele compared
with the other groups.
Overall, ApoE e4 was also associated with decline in
information processing speed rather than with memory de-
cline. Although memory decline is known to be an early
indicator of Alzheimer disease,10,11 slowing of information
processing may be an even earlier indicator. This is supported
by the processing-speed theory of Salthouse,35 which postu-
lates that slowing of information processing results in impair-
ments of higher-order cognitive functions, such as memory
and reasoning. Furthermore, the Coding Task was shown to
also measure components of memory, in addition to informa-
tion processing speed.36 In a previous study9 we showed that
ApoE e4 affected memory decline in cognitively impaired
elderly but not in cognitively normal elderly. The proportion
of cognitively normal elderly in the present study sample may
have masked the effect of ApoEe4 on memory decline.
Because the main interest of the present study was the effect
of ApoE e4 in stroke patients, we did not distinguish
cognitively impaired from cognitively normal subjects in this
study. This would have led to numbers that were too small for
analysis.
The strength of this study is that we used longitudinal data
from a large population-based study. As a consequence,
however, the stroke patients in this population-based study
may be more heterogeneous than stroke patients in clinical
studies. Moreover, more severe and complex stroke cases are
prone to nonresponse and loss to follow-up because of a
greater mortality of stroke patients during the study interval.
The stroke cases in our study are survivors of stroke.
Additional analyses showed, however, that the association
between ApoEe4 and baseline cognition did not differ for
nonsurvivors compared with survivors of stroke (data not
shown).
A limitation of this study is that we do not have specific
information on the type, size, and location of the stroke. The
majority of cases will suffer from ischemic stroke.31 Size1 and
side4 of the stroke may affect cognitive decline. However, the
severity of the stroke, which may be used as an indicator of
stroke size, did not affect the association between ApoEe4
and stroke regarding cognitive decline in our study.
This population-based study could not confirm the sugges-
tion that ApoEe4 modifies the effect of stroke on cognitive
decline. Recently, Haan et al12 reported that ApoEe4 in-
creased the effects of atherosclerotic disease on cognitive
decline. Although vascular events such as stroke are com-
monly seen as near the end stage of atherosclerotic disease,37
the mechanisms in the brain that cause cognitive decline after
stroke may be different from the mechanisms that cause
cognitive decline during atherosclerotic disease. ApoEe4
may affect cognitive decline in relation to atherosclerotic
disease, but it may not affect cognitive decline following
stroke. Our study suggests that stroke and ApoEe4 impair
cognition through distinct pathogenic mechanisms.
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